Champions Biotechnology UK Ltd. is a wholly owned subsidiary of Champions Biotechnology, Inc. (CBI), a public revenue-generating oncology drug development company with an innovative platform technology called Biomerk Tumorgrafts™, preclinical models of cancer that preserve the original characteristics of the human tumor. The company offers its predictive platform and tumor specific database to physicians to enhance personalized patient care and to BioPharma companies for evaluation of oncology drugs in a platform which integrates predictive testing with biomarker discovery.